Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Biologics Refreshes Management

Follows Departure Of Christine Hamacher As CEO

Executive Summary

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.

You may also be interested in...



Tambe Moves Up To Lead Biocon Biologics

Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.

Viatris And Biocon Line Up EU Bevacizumab

Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.

Biocon And Viatris Scoop EU Insulin Aspart Approval

Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel